Charles River secures five-year, $95.7m insourcing contract

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Iculig)
(Image: Getty/Iculig)

Related tags: Charles river laboratories, Research models, Preclinical contract research, Insourcing

Charles River will manage and provide staffing for NIAID’s vivarium and related research model operations to support biomedical research across multiple scientific disciplines.

The National Institute of Allergy and Infectious Diseases (NIAID) awarded the contract as part of the institute’s Division of Intramural Research animal care program.

The initial period extends through September 13, 2019, and includes annual renewal options for an additional four years, through September 13, 2023.

Charles River was not able to provide any further comment about any potential capacity increases to support the award.

According to the company, the contract is expected to generate incremental revenue of approximately $18m over the first year, with “modest increases”​ in subsequent periods. It is not anticipated to affect 2018 financial results.

As per the contact, Charles River’s Insourcing Solutions business will manage roughly 200 on-site, Charles River personnel supporting biomedical research across multiple scientific disciplines.

"Through strategic insourcing, NIAID will be able to leverage Charles River’s strong science and deep commitment to model care to drive their programs forward," ​Ann Murray, director, business development, Insourcing Solutions at Charles River told us.

Watch: The future of drug discovery? New tech, a focus on human biology, and partnerships

Services will be provided at various NIAID and other government facilities and include veterinary medical care, research model husbandry, technical support, data management, routine maintenance, sanitation, transportation, logistics, and administrative support, Murray explained.

“We believe that an increasing number of government and academic institutions, as well as biopharmaceutical clients, understand the value of utilizing our flexible and efficient staffing solutions,”​ said Charles River CEO and president James Foster in a press release.

Fueled by increasing investments from biotech, the company earlier this year​ said it expects to double the size of its business over the next five years – organically and through M&A – to become a more responsive partner.

In August, the Wilmington, MA-headquartered company reported a Q2 2018 revenue of $585.3m, marking a 24.8% increase over last year.

Related topics: Preclinical Research, Preclinical

Related news

Show more

Related products

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

Related suppliers

Follow us

Products

View more

Webinars